Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06775743
What this trial is testing

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Fudan University 53
Testing effectiveness (Phase 2)Study completedNCT00633750
What this trial is testing

Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Who this might be right for
Breast Cancer
Vanderbilt-Ingram Cancer Center 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT03122717
What this trial is testing

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Dana-Farber Cancer Institute 48
Large-scale testing (Phase 3)Study completedNCT02296125
What this trial is testing

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AstraZeneca 674
Testing effectiveness (Phase 2)Looking for participantsNCT07100106
What this trial is testing

Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 285
Testing effectiveness (Phase 2)Looking for participantsNCT05748834
What this trial is testing

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SCRI Development Innovations, LLC 36
Not applicableStudy completedNCT00897663
What this trial is testing

Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies

Who this might be right for
Brain and Central Nervous System Tumors
Alliance for Clinical Trials in Oncology 56
Testing effectiveness (Phase 2)Study completedNCT01491737
What this trial is testing

Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 258
Early research (Phase 1)Study completedNCT00574366
What this trial is testing

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Vanderbilt-Ingram Cancer Center 14
Early research (Phase 1)Ended earlyNCT01915524
What this trial is testing

Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Carcinoma
CureVac 26
Testing effectiveness (Phase 2)Ended earlyNCT01526928
What this trial is testing

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Locally Advanced or Metastatic Non Small Cell Lung Cancer
Clovis Oncology, Inc. 612
Post-approval studies (Phase 4)UnknownNCT02031601
What this trial is testing

Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Cancer
Qilu Hospital of Shandong University 250
Early research (Phase 1)Study completedNCT02529995
What this trial is testing

Phase I, Study in Chinese NSCLC Patients

Who this might be right for
Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive
AstraZeneca 31
Not applicableLooking for participantsNCT07180056
What this trial is testing

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Wenjin Yin 229
Early research (Phase 1)Study completedNCT01116336
What this trial is testing

Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck

Who this might be right for
Cancer of Head and NeckNeoplasms, Head and Neck
Emory University 25
Early research (Phase 1)Looking for participantsNCT06586957
What this trial is testing

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Who this might be right for
Solid TumorAdvanced Solid TumorSolid Tumor, Adult+25 more
NiKang Therapeutics, Inc. 150
Testing effectiveness (Phase 2)UnknownNCT03904823
What this trial is testing

Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

Who this might be right for
EGFR-mutant Non-Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 58
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Testing effectiveness (Phase 2)Study completedNCT00039182
What this trial is testing

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Who this might be right for
Advanced Malignant MesotheliomaEpithelial MesotheliomaRecurrent Malignant Mesothelioma+1 more
National Cancer Institute (NCI) 55
Testing effectiveness (Phase 2)Study completedNCT00044343
What this trial is testing

GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin

Who this might be right for
Colorectal Cancer
GlaxoSmithKline 80
Next Page